EMEA-003083-PIP01-21
Key facts
| Active substance |
Humanised IgG2k Fc-modified bispecific antibody against CD3 and BCMA (PF-06863135)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0564/2021
|
| PIP number |
EMEA-003083-PIP01-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Multiple Myeloma
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Pfizer Europe MA EEIG
E-mail: pip_enquiries@pfizer.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|